1,701 research outputs found
Upper airway cough syndrome
No full textPrevalence of rhinitis and postnasal drip syndrome in patients attending hospital-based clinics with chronic cough were reported between 6% and 87%. American College of Chest Physicians guidelines recommend the term 'upper airway cough syndrome' (UACS) instead of 'postnasal drip' because symptoms of upper airway and cough overlap in patiets with chronic cough. Presence or absence of postnasal drip does not include or exclude UACS as a cause of cough. Hence, the first step empirical treatment should include UACS therapy in all patients with chronic cough. The initial treatment for chronic cough is combination of a 'first-generation antihistamine and an oral decongestant' or 'intranasal corticosteroids and intranasal antihistaminic agents'. Improvement in cough with this combination serves as a treatment and as a diagnostic test for the presence of UACS. If postnasal drip and cough persist despite treatment in the first month, the patient could be unrecognized rhinosinusitis, or nasal polyposis and should planned nasal endoscopy (rhinoscopy) and sinus BT. If this tests will be normal, UACS is not the cause of the chronic cough
The prevalence and evaluation of premenstrual asthma, comparing premenstrual symptoms with asthmatic and healthy women
No full textTrends in prescribing montelukast in patients with asthma in real-life: Results from the Turkish adult asthma registry
No full textÇalışmada 97 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.76% (n = 1268; mean age: 46.2 ± 14.3 years), predominantly females (~76%), received montelukast. Montelukast users showed higher rates of allergic rhinitis (P < 0.001), hyper-sensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) (P = 0.008), and chronic rhinosi-nusitis (P = 0.008). Montelukast group also had higher atopy and total IgE levels and tended to be more eosinophilic. Montelukast was commonly preferred in allergic, eosinophilic, NSAID-exacerbated respiratory disease, and severe asthma phenotypes (P < 0.001). Patients receiving Steps 4 and 5 treatments are more likely to be prescribed montelukast (P < 0.001). Montelukast usage was higher among patients with uncontrolled asthma [ACT< 20 (OR:1.29, 95%CI:1.052–1.582, P = 0.014)]. In addition, logistic regression analyses identified the main factors associated with increased montelukast use as; female gender (OR:1.33, 95%CI:1.041–1.713, P = 0.02), presence of atopy (OR:1.46, 95%CI:1.157–1.864, P = 0.002), comorbid allergic rhinitis (OR:2.12, 95%CI:1.679–2.293, P < 0.001), and severe asthma (OR:2.18, 95%CI:1.712–2.784, P < 0.001). These findings reveal that montelukast use is prevalent among asthma patients, particularly in females, middle-aged adults, and those with comorbid allergic rhinitis, uncontrolled asthma, or specific asthma phenotypes, underscoring the factors that influence its prescription in asthma management
Venom allergy in Turkish beekeepers and risk factors for systemic reaction
No full textBu çalışma, 06-10, Haziran 2015 tarihlerinde Barcelona[İspanya]’da düzenlenen Congress of the European-Academy-of-Allergy-and-Clinical-Immunology Kongresi‘nde bildiri olarak sunulmuştur.European Acad Allergy & Clin Immuno
Impact of childhood diseases and familial asthma history on adult asthma characteristics: Results from turkish adult asthma registry (TAAR)
No full textBu çalışma, 08-11, Haziran 2023 tarihlerinde LocationHamburg[Almanya]’da düzenlenen Annual Hybrid Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) Kongresi‘nde bildiri olarak sunulmuştur.European Acad Allergy & Clin Immuno
Venom allergy, risk factors for systemic reactions and the knowledge levels among Turkish beekeepers
No full textBackground: Allergic reactions developing after bee sting can be severe and life-threatening. According to epidemiological data, serious systemic reactions range between 1.2%-3%, and this is 2-3 times higher (6%) in beekeeping. In different beekeepers' populations, risk factors of systemic reactions have been investigated and diverse results have been found.Objective: The aim of this study is to evaluate the level of knowledge of beekeepers about venom allergy, epidemiological data, systemic reaction rates, risk factors for systemic reactions, and the rate of emergency admissions after bee sting.Methods: With the collaboration of Uludag University Beekeeping Development Research Center and Beekeepers Association, a questionnaire consisting of 19 questions was applied to 242 beekeepers in Bursa and Yalova. Two hundred twenty-one beekeepers who completed the questionnaire were involved in the study.Results: The mean age of the beekeepers was 49.9 years range, 18-75 years). The systemic reaction to bee sting in beekeepers was 37.6%. Allergic rhinitis was found to be a risk factor for systemic reaction. Although 80% of the beekeepers recognized that bee venom could be lethal, only 60% of the beekeepers were aware of immunotherapy, and only 30% were aware of the adrenaline auto-injector drug.Conclusion: Similar to previous studies, we found that the systemic response to the bee sting in beekeepers was higher compared to normal population. Considering the occupational exposure to bee venom and thus higher risk, the awareness of venom allergy in this high risk population was low, and they were poorly informed about the treatment options
Country-based report: The safety of omalizumab treatment in pregnant patients with asthma
No full textBackground/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country. Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants. Results: Twenty pregnant patients and their 23 infant’s data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory volume in 1 s (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT), respectively. One patient gave birth to twin infants, two patients to two infants each in different years, and 17 to one infant each. Three (13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%) infants presented atopic diseases during their life. Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants
Fatigue: A forgotten symptom of asthma
No full textObjective Fatigue is a common symptom frequently reported in many disorders but little is known about the prevalence of fatigue in asthma. The objective of this study was to determine the prevalence of fatigue in asthmatic patients, the effect of fatigue on asthma quality of life and the relationship between fatigue and anxiety/depressionMaterials and methods This prospective cross-sectional study was conducted in Uludag University Faculty of Medicine, Department of Immunology and Allergic Diseases outpatient clinic from June 2019 to December 2019. Fatigue was assessed using the Checklist Individual Strength-Fatigue (CIS-Fatigue), psychological distress was assessed using the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI) and quality of life were assessed using the Asthma Quality of Life Questionnaire (AQLQ).Results In the present study, a total of 168 patients are included with an average age of 43.8 +/- 4.3 years. Nearly 64.8% of patients had controlled asthma and (35.2%) patients had uncontrolled asthma. Fatigue (CIS-Fatigue >= 27 points) was detected in 62.6% of patients and associated with asthma-related quality of life, asthma control, dyspnea, depression and anxiety (P < 0.05). However, the degree of lung function impairment and asthma severity were not associated with fatigue.Conclusions Fatigue as a symptom is common in asthmatic patients and correlates with asthma-related quality of life, asthma control, dyspnea, depression and anxiety. Future studies are needed to better understand the physical, psychological, behavioural and systemic factors that precipitate or perpetuate fatigue in asthma
Familial cases with hereditary angioedema type I (8 cases)
No full textBu çalışma, 06-10, Haziran 2015 tarihlerinde Barcelona[İspanya]’da düzenlenen Congress of the European-Academy-of-Allergy-and-Clinical-Immunology Kongresi‘nde bildiri olarak sunulmuştur.European Acad Allergy & Clin Immuno
Fatigue: A forgotten symptom of asthma
No full textBu çalışma, 10-12, Temmuz 2021 tarihlerinde Krakow[Polonya]’da düzenlenen Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) Kongresi‘nde bildiri olarak sunulmuştur.European Acad Allergy & Clin Immuno
- …
